Latest News
Ernexa Therapeutics Inc.
- Ernexa Therapeutics advances ERNA-101 cell ther...
- Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New 'What This Means” Segment
- ERNAW Warrants Hold Flat at $0.03 as Ernexa Therapeutics Buyers and Sellers Reach Equilibrium - Golden Cross
- Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series on October 15, Highlighting ERNA-101 Development
- Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
- Ernexa Therapeutics to present cell therapy pro...
- Ernexa completes safety studies for ERNA-101 cancer therapy By Investing.com
- Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
- Ernexa Therapeutics Selected for Emerging Track at 2026
Headlines from the last 30 days, linking to the original publishers. See all market news →